Drugs / Canvuparatide
Canvuparatide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06496217 | Jun 2024 → Sep 2025 | impaired renal function disease | MBX Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05158335 | Nov 2021 → Jun 2023 | — | MBX Biosciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06531941 | Oct 2024 → May 2027 expected | hypoparathyroidism | MBX Biosciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06465108 | Aug 2024 → May 2025 | hypoparathyroidism | MBX Biosciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07699471 Comparator | Aug 2026 → Jan 2028 expected | hypoparathyroidism | MBX Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | MBX Biosciences | Results MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism mbxbio.com ↗
today announced full results from the 12-week Avail™ Phase 2 trial and new one-year data from the ongoing open-label extension (OLE) study of once-weekly canvuparatide in adult patients with chronic hypoparathyroidism. |
All press releases naming this drug 4 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Canvuparatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07699471 ↗ |
| Known as | Canvuparatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068219 ↗ |
| Known as | MBX 2109 | “Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism” NCT07699471 ↗ |
| Action | Restore | “MBX 2109 is intended as a parathyroid hormone (PTH) replacement hormone” NCT06465108 ↗ |
| Modality | Protein / enzyme biologic | “MBX 2109 is intended as a parathyroid hormone (PTH) replacement hormone” NCT06465108 ↗ |
| Route | Subcutaneous | “taken as a subcutaneous (SC) injection just under the skin” NCT05158335 ↗ |